Literature DB >> 28803182

Subphenotypes of type 2 severe asthma in adults.

Masako Matsusaka1, Koichi Fukunaga1, Hiroki Kabata1, Kenji Izuhara2, Koichiro Asano3, Tomoko Betsuyaku1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28803182     DOI: 10.1016/j.jaip.2017.06.015

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  6 in total

1.  Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis.

Authors:  Giorgio Walter Canonica; Francesco Blasi; Nunzio Crimi; Pierluigi Paggiaro; Alberto Papi; Francesca Fanelli; Annalisa Stassaldi; Gianluca Furneri
Journal:  Clin Mol Allergy       Date:  2021-05-21

2.  Rapid and remarkable effectiveness of benralizumab for treating severe bronchial asthma with intractable eosinophilic rhinosinusitis and eosinophilic otitis media: A case report.

Authors:  Hideyasu Shimizu; Hisayuki Kato; Satoshi Yoshioka; Mitsushi Okazawa
Journal:  Respir Med Case Rep       Date:  2020-12-31

Review 3.  Feasibility of Discontinuing Biologics in Severe Asthma: An Algorithmic Approach.

Authors:  Kazuki Hamada; Keiji Oishi; Yoriyuki Murata; Tsunahiko Hirano; Kazuto Matsunaga
Journal:  J Asthma Allergy       Date:  2021-12-07

4.  Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study.

Authors:  Takanori Numata; Jun Araya; Hanae Miyagawa; Keitaro Okuda; Yu Fujita; Hirofumi Utsumi; Daisuke Takekoshi; Mitsuo Hashimoto; Shunsuke Minagawa; Takeo Ishikawa; Hiromichi Hara; Kazuyoshi Kuwano
Journal:  J Asthma Allergy       Date:  2021-06-03

Review 5.  Squamous Cell Carcinoma Antigen 2 (SCCA2, SERPINB4): An Emerging Biomarker for Skin Inflammatory Diseases.

Authors:  Kenji Izuhara; Yukie Yamaguchi; Shoichiro Ohta; Satoshi Nunomura; Yasuhiro Nanri; Yoshinori Azuma; Noriko Nomura; Yasuhiko Noguchi; Michiko Aihara
Journal:  Int J Mol Sci       Date:  2018-04-06       Impact factor: 5.923

6.  Three-step algorithm for biological therapy targeted IgE and IL-5 in severe asthma.

Authors:  Keiji Oishi; Kazuto Matsunaga
Journal:  Immun Inflamm Dis       Date:  2018-08-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.